FDA Grants Accelerated Approval of Novel Ovarian Cancer Therapy.

The article reports that the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx for adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior systemic treatment regimens. It mentions that Mirvetuximab soravtansine-gynx is a folate receptor alpha directed antibody and microtubule inhibitor conjugate for therapy based on an FDA-approved test.